Klin Farmakol Farm. 2004;18(1):26-29

Hyperhomocysteinémie a riziko ischemických cévních mozkových příhod

Ivanka Vlachová
Neurologická klinika FN a LF UP Olomouc

Keywords: hyperhomocysteinemia, stroke, risk factors, primary nad secundary prevention.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlachová I. Hyperhomocysteinémie a riziko ischemických cévních mozkových příhod. Klin Farmakol Farm. 2004;18(1):26-29.

Epidemiologické studie posledních let prokazují, že zvýšené koncentrace plazmatického homocysteinu představují nezávislý rizikový faktor ischemických mozkových příhod a kardivaskulárních onemocnění. Homocystein nepříznivě ovlivňuje cévní endotel a koagulační faktory. Asociace zvýšené hladiny homocysteinu s konvenčními rizikovými faktory aterosklerózy významně zvyšuje kardiovaskulární morbiditu i mortalitu. Vitaminovou substitucí foláty, vitaminy B6 a B12 lze hladiny homocysteinu snížit. Problematika možné primární a sekundární prevence, přes jisté pozitivní poznatky, zůstává v této oblasti otevřená. Přesto lze konstatovat, že cílená depistáž zvýšené hladiny homocysteinu a její ovlivnění má své místo zejména u rizikové populace.

hyperhomocysteinaemia and the risk of ischemic cerebral attacks

During the past year epidemiological studies have linked elevated plasma homocysteine concentrations as independent risk factor stroke and cardiovascular disease. Homocysteine negatively influences vascular endothelium and coagulation fractors. The association of increased homocysteine levels with conventional risk factors atherosclerosis increased cardiovascular morbitidy and mortality. Vitamin substitution of folates, vitamin B6 and B12 decreased homocysteine blood levels. The issue of their possible lowering within primary nad secondary prevention remains open. Still it can be concluded that specific homocysteine screening and influencing its levels is important, especially in high-risk population.

Download citation

References

  1. Bauer J. Terapie a prevence cévních mozkových příhod. Neurol pro praxi 2001; 4: 166-167.
  2. Zdravotnická ročenka České republiky 1999. ÚZIS ČR 2000; 212.
  3. WHO. WHO Technical Report 1994; 841: 15-16.
  4. Clarke R, Dally L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1449-1455. Go to original source... Go to PubMed...
  5. Goldstein LB, Adams R, Becker K, et al. Primary prevention of stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32: 280-299. Go to original source... Go to PubMed...
  6. Žák A. Homocystein a kardiovaskulární onemocnění. Ateroskleróza 2000; 4: 239-305.
  7. Hyánek J, Hoffmann R. Hyperhomocysteinémie a její diagnostický význam u cévních onemocnění. Prakt Flebol 1997; 2: 61-71.
  8. Guilland LC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease? 1. Basic data. Patol Biol 2003; 51: 101-110. Go to original source... Go to PubMed...
  9. Malinow MR. Homocysteine and arterial occlusive disease. J Intern Med 1994; 236: 603-609. Go to original source... Go to PubMed...
  10. Selhub J. Homocysteine metabolismus. Annu Rev Nutr 1999; 19: 217-246. Go to original source... Go to PubMed...
  11. McCully KS. Vascular pathology of homocysteinemia: Aplication for the pathology of arteriosclerosis. Am J Patol 1969; 53: 111-128.
  12. Boers GHJ, Smals AGH, Trijbels FM, et al. Heterozygosity for homocysteiuria in premature peripherial and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715. Go to original source... Go to PubMed...
  13. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willet WC, Stamfer MJ. A prospective study of plasma homocyst(e)ine and of ischemic stroke. Stroke 1994; 25: 1924-1930. Go to original source... Go to PubMed...
  14. Alfthan G, Pekkanen J, Jauhianinen J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in prospective Finnis population based study. Atherosclerosis 1994; 106: 9-19. Go to original source... Go to PubMed...
  15. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398. Go to original source... Go to PubMed...
  16. Giles WH, Groft JB, Greendlund KJ, et al. Total homocyst(e)ine concentration and the likelihood of non-fatal stroke: Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Stroke 1998; 29: 2473-2477. Go to original source... Go to PubMed...
  17. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 2000; 60: 491-499. Go to original source... Go to PubMed...
  18. Markus HS, Nadira A, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the Methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997; 28: 1739-1743. Go to original source... Go to PubMed...
  19. Morita H, Kurihara H, Tsubaki S, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Tromb Vasc Biol 1998; 18: 1465-1469. Go to original source... Go to PubMed...
  20. Spence JD, Malinow MR, Barnett PH, Marian AJ, Freeman D, Hegele RA. Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaq area. Stroke 1999; 30: 969-973. Go to original source... Go to PubMed...
  21. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology 2002; 59: 529-536. Go to original source... Go to PubMed...
  22. Malinow MR, Nieto J, Szklo M, Chambles LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults:the Atherosclerosis Risk in Communities study. Circulation 1993; 87: 1107-1113. Go to original source... Go to PubMed...
  23. Selhub J, Jacques PF, Boston AG, et al. Association between plasma homocysteine concentrations and extracranial carotid stenosis. N Engl J Med 1995; 332: 286-291. Go to original source... Go to PubMed...
  24. Aronow WS, Ahm C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial diseae in older persons. Am J Cardiol 1997; 149: 1432-1433. Go to original source... Go to PubMed...
  25. McIlroy, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk of stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33: 2351-2356. Go to original source... Go to PubMed...
  26. Fassbender K, Miuelke O, Bertsch T, Nafe B, Froschen S, Hennerici M. Homocysteine in cerebral makroangiopathy and mikroangiopathy. Lancet 1999; 1586-1587. Go to original source... Go to PubMed...
  27. Eikleboom JW, Hankey GJ, Anand SS, Lofthouse E, Stamples N, Baker RI. Association between high homocist(e)ine and ischemic stoke due to large- and small-artery dissease but not other etiologic subtypes of ischemic stroke. Stroke 2000; 31: 1069-1075. Go to original source... Go to PubMed...
  28. Ay H, Arsava EM, Tokgozoglu SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial trombus in stroke patients with nonvalvular atrial fibrillation. Stroke 2003; 34: 909-912. Go to original source... Go to PubMed...
  29. Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among preexisting coronary heart disease. Stroke 2003; 34: 632-636. Go to original source... Go to PubMed...
  30. Máchová L, Janout V, Vlachová I, Stránský Z, Ševčík J, Adam T. Prevalence hyperhomocysteinémie u osob s ischemickou cévní mozkovou příhodou, respektive tranzitorní ischemickou atakou-pilotní studie. Čes a slov Neurol Neurochir 2002; 2: 92-95.
  31. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independentely on traditional risk factors and C-reactive protein in patients with angiographicaly defined coronary artery disease. Circulation 2000; 102: 1227-1232. Go to original source... Go to PubMed...
  32. Auer JW, Berent R, Eber B, et al. Lack of association of increased C-reactive proteine and total plasma homocysteine. Circulation 2001; 104: 164 e. Go to original source...
  33. Lindgren A, Brattstrom L, Norving B, Hultberg B, Anderson A, Johansson BB. Plasma homocysteine in the acute and covalescent phases after stroke. Stroke 1995; 26: 795-800. Go to original source... Go to PubMed...
  34. Meiklejohn DJ, Vickers MA, Dijkhujsen R, Greaves M. Plasma homocysteine concentration in the acute and covalescent periods of atherothrombotic Stroke. Stroke 2001; 32: 57-62. Go to original source... Go to PubMed...
  35. Howard VJ, Sides EG, Newman GC, et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002; 33: 473-478. Go to original source... Go to PubMed...
  36. Dudman NP. An alternative view of homocysteine. Lancet 1999; 354: 2072-2074. Go to original source... Go to PubMed...
  37. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998; 29: 2478-2483. Go to original source... Go to PubMed...
  38. Del Ser T, Barba R, Herranz AS, et al. Hyperhomocyst(e)inemie is a risk factor of secondary vascular events in stroke patients. Cerebrovasc Dis 2001; 12: 91-98. Go to original source... Go to PubMed...
  39. Boysen G, Brander T, Christiansen H, Gideon R, Truelsen T. Homocysteine and risk of reccurent stroke. Stroke 2003; 34: 1258-1261. Go to original source... Go to PubMed...
  40. Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML.Serum folate and risk for ischemic stroke. First National healt and Nutricion Examination Survey epidemiologic follow-up study. Stroke 1995; 26: 1166-1170. Go to original source... Go to PubMed...
  41. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from the diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-364. Go to original source... Go to PubMed...
  42. Loria CM, Ingram DC, Feldman JJ, Wright JD, Madams JH. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 2000; 160: 3258-3262. Go to original source... Go to PubMed...
  43. Bozzano LA, He J, Ogden LG, et al. Dietary intake of folate and risk of stroke in US men and women. NHANES I Epidemiologic follow-up Study. Stroke 2002; 33: 1183-1189. Go to original source... Go to PubMed...
  44. van Guldener C, Stehouwer CD. Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother 2001; 2: 1449-1460. Go to original source... Go to PubMed...
  45. Kasner SE. Folate and risk of stroke: Fortify first and ask Questions later? Stroke 2002; 33: 1188-1189. Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.